Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States
Vaccines · 12.01.2024 · 12 (1) · 74
DOI: 10.3390/vaccines12010074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 12.01.2024. Verfasst von Kyle Paret und 5 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, NC 27709, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novavax (United States).
Abstract (Originalsprache)
Policymakers in the United States (US) recommend coronavirus disease 2019 (COVID-19) vaccination with a monovalent 2023–2024 vaccine formulation based on the Omicron XBB.1.5 variant. We estimated the potential US population-level health and economic impacts of increased COVID-19 vaccine coverage that might be expected with the availability of a protein-based vaccine with simpler storage requirements in addition to messenger ribonucleic acid (mRNA) vaccines. A Markov model was developed to estimate 1-year COVID-19-related costs, cases, hospitalizations, and deaths with and without the availability of a protein-based vaccine option. The model population was stratified by age and risk status. Model inputs were sourced from published literature or derived from publicly available data. Our model estimated that a five-percentage-point increase in coverage due to the availability of a protein-based vaccine option would prevent over 500,000 cases, 66,000 hospitalizations, and 3000 COVID-19-related deaths. These clinical outcomes translated to 42,000 quality-adjusted life years (QALYs) gained and an incremental cost–effectiveness ratio of USD 16,141/QALY from a third-party payer perspective. In sensitivity analyses, outcomes were most sensitive to COVID-19 incidence and severity across age groups. The availability of a protein-based vaccine option in the US could reduce hospitalizations and deaths and is predicted to be cost-effective.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RTI Health Solutions, Research Triangle Park, NC 27709, USA.
- Novavax, Inc., Gaithersburg, MD 20878, USA.
- Karolinska Institute, 17177 Stockholm, Sweden.
ORCID-Profile: William L Herring, Lesley G Shane, Matthew D Rousculp
Förderung
- Novavax (United States)
Zitieren
APA
Paret, K., Beyhaghi, H., Herring, W. L., Mauskopf, J., Shane, L. G., & Rousculp, M. D. (2024). Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States. Vaccines, 12(1), 74. https://doi.org/10.3390/vaccines12010074
Vancouver
Paret K, Beyhaghi H, Herring WL, Mauskopf J, Shane LG, Rousculp MD. Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States. Vaccines. 2024;12(1):74. doi:10.3390/vaccines12010074
BibTeX
@article{Paret2024,
author = {Paret, Kyle and Beyhaghi, Hadi and Herring, William L and Mauskopf, Josephine and Shane, Lesley G and Rousculp, Matthew D},
title = {Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {1},
pages = {74},
doi = {10.3390/vaccines12010074}
}
EUVIMED